---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-025867"
form_type: "8-K"
ticker: "OFIX"
cik: "0000884624"
company_name: "Orthofix Medical Inc."
filed_at: "2024-03-05T23:59:59+00:00"
generated_at: "2026-06-05T04:27:58.683116+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Orthofix Q4 net sales $200.4M (+7% pro forma constant currency); FY24 guidance implies 5-7% growth

## Summary
- Q4 net sales $200.4M; Bone Growth Therapies up 15% YoY; U.S. spine fixation up 13.5%.
- Q4 net loss $(22.2)M ($(0.59)/share); Non-GAAP adjusted EBITDA $19.6M (9.8% of sales), up 96% YoY pro forma.
- Full-year 2023 net sales $746.6M; net loss $(151.4)M; adjusted EBITDA $46.3M (6.2% of sales), up 69%.
- FY24 guidance: net sales $785M-$795M (5-7% constant currency growth); adjusted EBITDA $62M-$67M; exit Q4 FCF positive.
- Achieved $32M in annualized merger-related synergies; cash $37.8M, $100M drawn on $150M credit facility.

## SEC filing metadata
- accession: 0000950170-24-025867
- form_type: 8-K
- ticker: OFIX
- cik: 0000884624
- company_name: Orthofix Medical Inc.
- filed_at: 2024-03-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/884624/000095017024025867/0000950170-24-025867-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/884624/000095017024025867/ofix-20240305.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-025867
- JSON: https://secwatch.observer/filing/0000950170-24-025867.json
- Plain text: https://secwatch.observer/filing/0000950170-24-025867.txt

## Key facts
- Earnings Releases
  Orthofix Medical Inc. reported the fourth quarter and year ended December 31, 2023 results: revenue $200.4 million, net income $(22.2) million, EPS $(0.59).
  - Period: the fourth quarter and year ended December 31, 2023
  - Revenue: $200.4 million
  - Net income: $(22.2) million
  - EPS: $(0.59)
  - Result: reported results
  source text: Fourth quarter net sales were $200.4 million, an increase of 64% on a reported basis and 7% on a pro forma constant currency basis. Net loss was $(22.2) million and earnings per share ("EPS") was $(0.59) on a reported basis, representing an improvement of 19% when compared to pro forma results for the prior year period.
  evidence_url: https://www.sec.gov/Archives/edgar/data/884624/000095017024025867/0000950170-24-025867-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.